#United States #San Francisco #Securities Fraud #Capricor Therapeutics #DMD treatment

Capricor Therapeutics Facing Legal Challenges

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is at the center of a securities fraud class action lawsuit that has caught the attention of investors and analysts alike. Prominent national investor rights law firm, Hagens Berman, is highlighting the significant losses suffered by shareholders following the company's recent financial disclosures. With a deadline looming for potential lead plaintiffs in the class action on September 28, 2026, this case has developed into a critical event for those financially impacted.

Unfolding Developments

Recently, Capricor released its Q2 2026 earnings, revealing a staggering net loss of $40.7 million. More notably, the earnings call lacked a live Q&A session with analysts, causing ripples of concern among investors. Capricor management attributed this decision to ongoing sensitive discussions with the FDA regarding their regulatory path forward, a move that many interpret as an attempt to shield itself from scrutiny about concerning trial data.

This situation has led to rising doubts about the integrity of trial data associated with their lead product, Deramiocel, aimed at treating Duchenne muscular dystrophy (DMD). By avoiding open communication with analysts, Capricor has left considerable questions unanswered, particularly concerning the implications of recent legal and regulatory pressures.

Class Action Lawsuit Details

The filed class action lawsuit claims that during the class period from December 17, 2025, to July 26, 2026, Capricor and select executives made materially false and misleading statements regarding their clinical trial data and regulatory pathway.

Critically, the lawsuit accuses management of failing to disclose modifications made to their pre-specified Statistical Analysis Plan (SAP) required by the U.S. FDA, which were implemented without consent. This change casts doubt on the validity of the data supporting the efficacy of Deramiocel, especially against the backdrop of its intended goal of ameliorating the symptoms of DMD.

A Series of Events Leading to Investor Discontent

An announcement on December 3, 2025, indicated promising results from the pivotal Phase 3 HOPE-3 study of Deramiocel. Following the announcement, Capricor's stock surged by 370%, peaking at $23.60. The company subsequently initiated a public offering of approximately six million shares at a market price of $25, banking on investor optimism fueled by the study results.

However, that optimism was rapidly erased when the FDA released briefing documents on July 27, 2026, indicating that the HOPE-3 study had failed to meet its primary and secondary objectives. The stock plummeted by about 64% in a day, closing at $7.00 following an Advisory Committee that voted 9-3 against the drug's efficacy, leading to a cascade of financial losses for investors.

Hagens Berman's Investigation

Reed Kathrein, a partner at Hagens Berman, emphasized the firm's commitment to, "focusing on investors' losses and revealing how management characterized these trial endpoints along with any undisclosed alterations." Investors are urged to consider their options as Hagens Berman actively investigates these serious allegations.

Rights of Affected Investors

Time is of the essence for investors who endured financial setbacks due to their engagement with Capricor securities within the defined timeframe. With the lead plaintiff deadline approaching, impacted individuals are encouraged to take action swiftly.

Hagens Berman has provided several avenues for affected shareholders to make their voices heard, including submitting information online or contacting their office directly for a clearer pathway toward recovery.

For anyone with knowledge about the case or non-public information regarding Capricor, there are also avenues available to assist in these legal proceedings. The SEC's Whistleblower program may offer rewards for providing original information, reflecting the seriousness of the situation at hand.

Conclusion

The unfolding story surrounding Capricor Therapeutics serves as an important reminder of the complexities and risks associated with investing in emerging biotech firms. As shareholders grapple with uncertainty and substantial financial losses, the outcomes of the class action lawsuit may play a pivotal role in shaping future investor confidence. Thus, it raises substantial questions about the necessary checks and balances in the biotech industry's pursuit of innovative treatments.